文献速递炎症性肠病

英夫利西单抗暴露与克罗恩病影像学愈合相关

Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-28

本文为 TAILORIX 试验的亚组研究,分析活动性管腔型克罗恩病患者基线及第54周磁共振小肠造影(MRE)数据,采用 MaRIA 评分评估影像学应答与缓解;结果显示第14周英夫利西单抗谷浓度与影像学缓解及应答相关,且持续谷浓度高于5.0 μg/mL与影像学应答相关。

要点

  • 第14周谷浓度7.8 μg/mL与第54周影像学缓解及应答相关。
  • 各时间点谷浓度均高于5.0 μg/mL与影像学应答相关。
  • 第54周时内镜与 MaRIA 评分无相关性。

核心结论

  • 在活动性管腔型克罗恩病患者的 TAILORIX 亚组中,英夫利西单抗暴露与影像学结局之间存在关联。

研究设计与样本

  • TAILORIX 试验亚组研究,纳入欧洲活动性管腔型克罗恩病并接受英夫利西单抗治疗的患者,分析基线及第54周 MRE 数据,由盲法中心阅片者按 MaRIA 评分评估。

主要发现

  • 共分析36例患者,女性占50%,中位年龄35.7岁,中位病程1.5个月。
  • 第54周时36.4%患者有影像学应答,30.3%达影像学缓解,71%达内镜缓解。
  • 基线 CDAI 与 MaRIA 评分相关(κ=0.46;P=.008),第54周无相关(κ=0.06;P=.75)。
  • 影像学缓解与第14周谷浓度相关(P=.049),界值7.8 μg/mL(AUC 0.74;敏感度75%;特异度86%;阴性预测值90%;阳性预测值57%)。
  • 影像学应答与第14周谷浓度相关(P=.048),界值7.8 μg/mL(AUC 0.73;敏感度70%;特异度90%;阴性预测值86%;阳性预测值78%),亦与各时间点谷浓度均高于5.0 μg/mL相关(P=.034)。

关键数值与推荐

  • 影像学缓解定义为所有肠段 MaRIA 评分低于7,影像学应答定义为低于11。
  • 第14周英夫利西单抗谷浓度界值7.8 μg/mL 与第54周影像学缓解和应答相关。
  • 各时间点谷浓度持续高于5.0 μg/mL 与影像学应答相关。

临床怎么用

  • 对活动性管腔型克罗恩病使用英夫利西单抗者,可关注第14周谷浓度是否达到7.8 μg/mL 及是否持续高于5.0 μg/mL,以辅助预判影像学愈合。

局限性

  • 为 TAILORIX 试验亚组研究,样本量36例,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Higher infliximab trough levels are associated with clinical and endoscopic remission in patients with Crohn's disease (CD). We investigated pharmacodynamic features of infliximab and radiological healing. METHODS: We performed a substudy of the TAILORIX trial (patients with active luminal CD in Europe, treated with infliximab), analyzing baseline and week 54 magnetic resonance enterography (MRE) data. MREs were scored using the MaRIA score by blinded central readers. Radiologic response and remission were defined, based on MaRIA criteria in all segments, as scores below 11 and 7, respectively. We collected data on infliximab trough levels, biomarkers, and endoscopic findings. Our primary aim was to evaluate pharmacodynamic features associated with radiologic response and remission, based on MRE assessments at baseline and at 54 weeks after initiation of infliximab therapy. RESULTS: We analyzed data from 36 patients (50% female; median age 35.7 years; interquartile age range, 25.6-48.6 years; median disease duration, 1.5 months; interquartile duration range, 0.6-22.4 months). At week 54 of treatment, 36.4% of patients had a radiologic response, 30.3% of patients were in remission, and 71% had endoscopic features of remission. At baseline, there was a correlation between the CD endoscopic index of severity and MaRIA scores (κ = 0.46; P = .008), but we found no correlation at week 54 (κ = 0.06; P = .75). Radiologic remission correlated with infliximab trough level at week 14 (P = .049) when the infliximab trough level cut-off value was set at 7.8 μg/mL (area under the curve, 0.74; 75% sensitivity; 86% specificity; 90% negative predictive value; 57% positive predictive value). Radiologic response correlated with infliximab trough levels at week 14 (P = .048) when the infliximab trough level cut-off value was set at 7.8 μg/mL (area under the curve, 0.73; 70% sensitivity; 90% specificity; 86% negative predictive value; 78% positive predictive value) and with continuous pharmacologic evidence of response (infliximab trough levels above 5.0 μg/mL at all time points) (P = .034). CONCLUSIONS: In a substudy of data from the TAILORIX trial of patients with active luminal CD, we identified a relationship between exposure to infliximab and radiologic evidence of outcomes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bossuyt P, Dreesen E, Rimola J, et al. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32360982. doi:10.1016/j.cgh.2020.04.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。